Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Acquired by Impax Asset Management Group plc

Impax Asset Management Group plc lifted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 25.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,000,000 shares of the company's stock after buying an additional 400,000 shares during the quarter. Impax Asset Management Group plc owned approximately 0.27% of Roivant Sciences worth $23,080,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of ROIV. nVerses Capital LLC purchased a new stake in shares of Roivant Sciences during the second quarter worth about $34,000. Point72 Hong Kong Ltd purchased a new stake in Roivant Sciences during the 2nd quarter worth approximately $36,000. US Bancorp DE raised its holdings in shares of Roivant Sciences by 146.5% during the third quarter. US Bancorp DE now owns 3,278 shares of the company's stock valued at $38,000 after acquiring an additional 1,948 shares during the last quarter. Quarry LP purchased a new position in shares of Roivant Sciences in the second quarter valued at approximately $53,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Roivant Sciences in the first quarter worth approximately $72,000. Hedge funds and other institutional investors own 64.76% of the company's stock.

Insider Transactions at Roivant Sciences

In related news, CAO Rakhi Kumar sold 250,000 shares of Roivant Sciences stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $11.89, for a total value of $2,972,500.00. Following the completion of the sale, the chief accounting officer now owns 209,322 shares in the company, valued at approximately $2,488,838.58. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Roivant Sciences news, CEO Matthew Gline sold 1,983,257 shares of the business's stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $11.79, for a total value of $23,382,600.03. Following the completion of the transaction, the chief executive officer now owns 17,870,543 shares in the company, valued at $210,693,701.97. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CAO Rakhi Kumar sold 250,000 shares of Roivant Sciences stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $11.89, for a total value of $2,972,500.00. Following the completion of the transaction, the chief accounting officer now owns 209,322 shares of the company's stock, valued at approximately $2,488,838.58. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,577,309 shares of company stock worth $42,151,184. 7.90% of the stock is currently owned by insiders.

Roivant Sciences Trading Up 1.1 %

NASDAQ:ROIV traded up $0.13 on Tuesday, reaching $11.66. The company's stock had a trading volume of 2,531,828 shares, compared to its average volume of 5,855,325. Roivant Sciences Ltd. has a 12-month low of $8.47 and a 12-month high of $13.06. The stock has a 50 day moving average price of $11.81 and a 200 day moving average price of $11.28. The firm has a market cap of $8.62 billion, a price-to-earnings ratio of 2.10 and a beta of 1.24. The company has a quick ratio of 27.91, a current ratio of 27.91 and a debt-to-equity ratio of 0.05.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.33. The firm had revenue of $55.10 million for the quarter, compared to analyst estimates of $30.72 million. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. Roivant Sciences's revenue was up 155.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.38) EPS. On average, equities analysts anticipate that Roivant Sciences Ltd. will post -1.14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on ROIV. HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Thursday, September 19th. Cantor Fitzgerald restated an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Bank of America increased their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a "neutral" rating in a report on Wednesday, September 11th. Finally, Piper Sandler boosted their target price on Roivant Sciences from $20.00 to $22.00 and gave the stock an "overweight" rating in a report on Wednesday, July 10th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Roivant Sciences presently has an average rating of "Moderate Buy" and an average price target of $17.39.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.